Literature DB >> 21575989

Meeting report of the first conference of the International Placenta Stem Cell Society (IPLASS).

O Parolini1, F Alviano, A G Betz, D W Bianchi, C Götherström, U Manuelpillai, A L Mellor, R Ofir, P Ponsaerts, S A Scherjon, M L Weiss, S Wolbank, K J Wood, C V Borlongan.   

Abstract

The International Placenta Stem Cell Society (IPLASS) was founded in June 2010. Its goal is to serve as a network for advancing research and clinical applications of stem/progenitor cells isolated from human term placental tissues, including the amnio-chorionic fetal membranes and Wharton's jelly. The commitment of the Society to champion placenta as a stem cell source was realized with the inaugural meeting of IPLASS held in Brescia, Italy, in October 2010. Officially designated as an EMBO-endorsed scientific activity, international experts in the field gathered for a 3-day meeting, which commenced with "Meet with the experts" sessions, IPLASS member and board meetings, and welcome remarks by Dr. Ornella Parolini, President of IPLASS. The evening's highlight was a keynote plenary lecture by Dr. Diana Bianchi. The subsequent scientific program consisted of morning and afternoon oral and poster presentations, followed by social events. Both provided many opportunities for intellectual exchange among the 120 multi-national participants. This allowed a methodical and deliberate evaluation of the status of placental cells in research in regenerative and reparative medicine. The meeting concluded with Dr. Parolini summarizing the meeting's highlights. This further prepared the fertile ground on which to build the promising potential of placental cell research. The second IPLASS meeting will take place in September 2012 in Vienna, Austria. This meeting report summarizes the thought-provoking lectures delivered at the first meeting of IPLASS.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21575989      PMCID: PMC4437622          DOI: 10.1016/j.placenta.2011.04.017

Source DB:  PubMed          Journal:  Placenta        ISSN: 0143-4004            Impact factor:   3.481


  48 in total

1.  Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.

Authors:  Katarina Le Blanc; Ida Rasmusson; Berit Sundberg; Cecilia Götherström; Moustapha Hassan; Mehmet Uzunel; Olle Ringdén
Journal:  Lancet       Date:  2004-05-01       Impact factor: 79.321

2.  Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources.

Authors:  Mehdi Najar; Gordana Raicevic; Hicham Id Boufker; Hussein Fayyad Kazan; Cécile De Bruyn; Nathalie Meuleman; Dominique Bron; Michel Toungouz; Laurence Lagneaux
Journal:  Cell Immunol       Date:  2010-06-18       Impact factor: 4.868

3.  Stem cell characteristics of amniotic epithelial cells.

Authors:  Toshio Miki; Thomas Lehmann; Hongbo Cai; Donna B Stolz; Stephen C Strom
Journal:  Stem Cells       Date:  2005-08-04       Impact factor: 6.277

4.  Osteogenic differentiation of intact human amniotic membrane.

Authors:  Andrea Lindenmair; Susanne Wolbank; Guido Stadler; Alexandra Meinl; Anja Peterbauer-Scherb; Johann Eibl; Helene Polin; Christian Gabriel; Martijn van Griensven; Heinz Redl
Journal:  Biomaterials       Date:  2010-08-17       Impact factor: 12.479

5.  Amniotic membrane application reduces liver fibrosis in a bile duct ligation rat model.

Authors:  Luciana B Sant'Anna; Anna Cargnoni; Lorenzo Ressel; Graziella Vanosi; Ornella Parolini
Journal:  Cell Transplant       Date:  2010-08-18       Impact factor: 4.064

Review 6.  Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy.

Authors:  Burles A Johnson; Babak Baban; Andrew L Mellor
Journal:  Immunotherapy       Date:  2009-07       Impact factor: 4.196

7.  Allogeneic stromal cell implantation in brain tissue leads to robust microglial activation.

Authors:  Bart R Tambuyzer; Irene Bergwerf; Nathalie De Vocht; Kristien Reekmans; Jasmijn Daans; Philippe G Jorens; Herman Goossens; Dirk K Ysebaert; Shyama Chatterjee; Eric Van Marck; Zwi N Berneman; Peter Ponsaerts
Journal:  Immunol Cell Biol       Date:  2009-03-17       Impact factor: 5.126

8.  Transplantation of allogeneic and xenogeneic placenta-derived cells reduces bleomycin-induced lung fibrosis.

Authors:  Anna Cargnoni; Lucia Gibelli; Alessandra Tosini; Patrizia Bonassi Signoroni; Claudia Nassuato; Davide Arienti; Guerino Lombardi; Alberto Albertini; Georg S Wengler; Ornella Parolini
Journal:  Cell Transplant       Date:  2009       Impact factor: 4.064

9.  Fetomaternal cell trafficking and the stem cell debate: gender matters.

Authors:  Diana W Bianchi; Nicholas M Fisk
Journal:  JAMA       Date:  2007-04-04       Impact factor: 56.272

Review 10.  T regulatory cells and the control of alloimmunity: from characterisation to clinical application.

Authors:  Joanna Wieckiewicz; Ryoichi Goto; Kathryn J Wood
Journal:  Curr Opin Immunol       Date:  2010-09-23       Impact factor: 7.486

View more
  7 in total

1.  Stroke therapy: the potential of amniotic fluid-derived stem cells.

Authors:  Maya Elias; Jaclyn Hoover; Hung Nguyen; Stephanny Reyes; Christopher Lawton; Cesar V Borlongan
Journal:  Future Neurol       Date:  2015

2.  Human amnion favours tissue repair by inducing the M1-to-M2 switch and enhancing M2 macrophage features.

Authors:  Marta Magatti; Elsa Vertua; Silvia De Munari; Marta Caro; Maddalena Caruso; Antonietta Silini; Mario Delgado; Ornella Parolini
Journal:  J Tissue Eng Regen Med       Date:  2016-07-11       Impact factor: 3.963

3.  Intravenous Grafts of Human Amniotic Fluid-Derived Stem Cells Reduce Behavioral Deficits in Experimental Ischemic Stroke.

Authors:  Tatiana Taís Sibov; Lorena Favaro Pavon; Francisco Romero Cabral; Ivone Farias Cunha; Daniela Mara de Oliveira; Jean Gabriel de Souza; Luciana Cavalheiro Marti; Edgar Ferreira da Cruz; Jackeline Moraes Malheiros; Fernando F Paiva; Alberto Tannús; Sérgio Mascarenhas de Oliveira; Marcos Devanir Silva da Costa; Patrícia A Dastoli; Jardel N Mendonça; Silvia Regina Caminada de Toledo; Suzana M Fleury Malheiros; Manoel Antonio de Paiva Neto; Nelma Bastos Bezerra Rego; Antônio Fernandes Moron; Sérgio Cavalheiro
Journal:  Cell Transplant       Date:  2019-06-04       Impact factor: 4.064

4.  Human Placental-Derived Adherent Stromal Cells Co-Induced with TNF-α and IFN-γ Inhibit Triple-Negative Breast Cancer in Nude Mouse Xenograft Models.

Authors:  Hoshea Allen; Niva Shraga-Heled; Michal Blumenfeld; Tamar Dego-Ashto; Dana Fuchs-Telem; Ariel Gilert; Zami Aberman; Racheli Ofir
Journal:  Sci Rep       Date:  2018-01-12       Impact factor: 4.379

5.  The effect of human placental chorionic villi derived mesenchymal stem cell on triple-negative breast cancer hallmarks.

Authors:  Alaa T Alshareeda; Emad Rakha; Ayidah Alghwainem; Bahauddeen Alrfaei; Batla Alsowayan; Abdullah Albugami; Abdullah M Alsubayyil; Mohmed Abomraee; Nur Khatijah Mohd Zin
Journal:  PLoS One       Date:  2018-11-20       Impact factor: 3.240

Review 6.  Amnion-derived stem cell transplantation: A novel treatment for neurological disorders.

Authors:  Horacio G Carvajal; Paola Suárez-Meade; Cesario V Borlongan
Journal:  Brain Circ       Date:  2016-03-11

7.  The Human Amniotic Mesenchymal Stem Cells (hAMSCs) Improve the Implant Osseointegration and Bone Regeneration in Maxillary Sinus Floor Elevation in Rabbits.

Authors:  Lu Yin; Zhi-Xuan Zhou; Ming Shen; Ning Chen; Fei Jiang; Shou-Lin Wang
Journal:  Stem Cells Int       Date:  2019-12-11       Impact factor: 5.443

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.